STOCK TITAN

[SCHEDULE 13G] BTC Digital Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

On 07/15/2025, CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. jointly filed a Schedule 13G reporting a passive ownership of 1,000,000 BriaCell Therapeutics Corp. common shares (CUSIP 107930208). The stake equals 5.7 % of the 17.55 M shares outstanding, as cited in BriaCell’s July 2025 prospectus. Each Reporting Person claims 0 sole and 1,000,000 shared voting and dispositive power. Both entities disclaim beneficial ownership beyond their pecuniary interest and certify the shares were not acquired to influence control. Signatory: Sarah Travis (Heights Capital) on 07/22/2025. No group arrangements, subsidiaries, or additional controlling interests are disclosed.

Il 15/07/2025, CVI Investments, Inc. e il suo gestore degli investimenti Heights Capital Management, Inc. hanno presentato congiuntamente un Schedule 13G dichiarando una posizione passiva di 1.000.000 di azioni ordinarie di BriaCell Therapeutics Corp. (CUSIP 107930208). La partecipazione rappresenta il 5,7% delle 17,55 milioni di azioni in circolazione, come indicato nel prospetto di BriaCell di luglio 2025. Ogni soggetto dichiarante detiene 0 poteri di voto e disposizione esclusivi e 1.000.000 condivisi. Entrambe le entità escludono la proprietà effettiva oltre il loro interesse economico e certificano che le azioni non sono state acquisite per influenzare il controllo. Firmataria: Sarah Travis (Heights Capital) il 22/07/2025. Non sono stati dichiarati accordi di gruppo, controllate o altri interessi di controllo.

El 15/07/2025, CVI Investments, Inc. y su gestor de inversiones Heights Capital Management, Inc. presentaron conjuntamente un Schedule 13G reportando una posesión pasiva de 1,000,000 acciones ordinarias de BriaCell Therapeutics Corp. (CUSIP 107930208). La participación equivale al 5.7% de las 17.55 millones de acciones en circulación, según el prospecto de BriaCell de julio de 2025. Cada persona informante declara 0 poder de voto y disposición exclusivo y 1,000,000 compartidos. Ambas entidades niegan la propiedad beneficiaria más allá de su interés económico y certifican que las acciones no fueron adquiridas para influir en el control. Firmante: Sarah Travis (Heights Capital) el 22/07/2025. No se revelan arreglos grupales, subsidiarias ni otros intereses de control adicionales.

2025년 7월 15일, CVI Investments, Inc.와 투자 관리자 Heights Capital Management, Inc.는 공동으로 Schedule 13G를 제출하여 1,000,000주 BriaCell Therapeutics Corp. 보통주 (CUSIP 107930208)에 대한 수동적 소유권을 보고했습니다. 이 지분은 BriaCell의 2025년 7월 투자설명서에 명시된 17.55백만 주 중 5.7%에 해당합니다. 각 보고자는 단독 투표 및 처분 권한 0주공동 투표 및 처분 권한 1,000,000주를 주장합니다. 양 기관은 금전적 이익을 초과하는 실질적 소유권을 부인하며, 주식이 지배권 영향을 목적으로 취득되지 않았음을 인증합니다. 서명자: Sarah Travis (Heights Capital), 2025년 7월 22일. 그룹 협약, 자회사 또는 추가 지배권은 공개되지 않았습니다.

Le 15/07/2025, CVI Investments, Inc. et son gestionnaire d'investissement Heights Capital Management, Inc. ont conjointement déposé un Schedule 13G déclarant une participation passive de 1 000 000 actions ordinaires de BriaCell Therapeutics Corp. (CUSIP 107930208). Cette participation représente 5,7 % des 17,55 millions d'actions en circulation, comme indiqué dans le prospectus de BriaCell de juillet 2025. Chaque personne déclarante revendique 0 pouvoir de vote et de disposition exclusif et 1 000 000 partagé. Les deux entités déclinent toute propriété bénéficiaire au-delà de leur intérêt pécuniaire et certifient que les actions n'ont pas été acquises pour influencer le contrôle. Signataire : Sarah Travis (Heights Capital) le 22/07/2025. Aucun accord de groupe, filiale ou autre intérêt de contrôle n’est divulgué.

Am 15.07.2025 reichten CVI Investments, Inc. und ihr Investmentmanager Heights Capital Management, Inc. gemeinsam ein Schedule 13G ein, in dem ein passives Eigentum von 1.000.000 BriaCell Therapeutics Corp. Stammaktien (CUSIP 107930208) gemeldet wurde. Der Anteil entspricht 5,7 % der 17,55 Mio. ausstehenden Aktien, wie im Juli 2025 veröffentlichten Prospekt von BriaCell angegeben. Jede meldende Person beansprucht 0 alleinige und 1.000.000 gemeinsame Stimm- und Verfügungsrechte. Beide Einheiten lehnen eine wirtschaftliche Eigentümerschaft über ihr finanzielles Interesse hinaus ab und bestätigen, dass die Aktien nicht zum Zweck der Einflussnahme auf die Kontrolle erworben wurden. Unterzeichnerin: Sarah Travis (Heights Capital) am 22.07.2025. Es werden keine Gruppenvereinbarungen, Tochtergesellschaften oder weitere Kontrollinteressen offengelegt.

Positive
  • Institutional ownership disclosed: CVI Investments & Heights Capital now publicly report a 5.7 % stake (1 M shares), increasing transparency of BriaCell’s shareholder base.
Negative
  • None.

Insights

TL;DR: 5.7 % passive stake disclosed; institutional holder presence is neutral-to-slightly positive, no control intentions stated.

The filing introduces CVI/Heights Capital as a mid-sized shareholder, now above the 5 % reporting threshold. Shared, not sole, authority implies a coordinated but non-controlling position. Because the investment is certified as passive, no immediate strategic shift or activist pressure should be expected. From a liquidity perspective, 1 M shares represent modest ownership relative to BriaCell’s float, signalling limited market impact. Overall, disclosure enhances transparency but is not materially transformational.

TL;DR: Disclosure improves ownership clarity; passive stance lowers governance risk—overall neutral governance impact.

Schedule 13G confirms the investors’ passive status under Rule 13d-1(c), alleviating concerns of an unsolicited takeover attempt. Shared voting/dispositive power is typical for an investment manager structure and aligns with SEC requirements. The disclaimer of beneficial ownership beyond pecuniary interest further limits potential governance influence. No group formation, subsidiary involvement, or control-seeking language appears, suggesting standard institutional investment behaviour.

Il 15/07/2025, CVI Investments, Inc. e il suo gestore degli investimenti Heights Capital Management, Inc. hanno presentato congiuntamente un Schedule 13G dichiarando una posizione passiva di 1.000.000 di azioni ordinarie di BriaCell Therapeutics Corp. (CUSIP 107930208). La partecipazione rappresenta il 5,7% delle 17,55 milioni di azioni in circolazione, come indicato nel prospetto di BriaCell di luglio 2025. Ogni soggetto dichiarante detiene 0 poteri di voto e disposizione esclusivi e 1.000.000 condivisi. Entrambe le entità escludono la proprietà effettiva oltre il loro interesse economico e certificano che le azioni non sono state acquisite per influenzare il controllo. Firmataria: Sarah Travis (Heights Capital) il 22/07/2025. Non sono stati dichiarati accordi di gruppo, controllate o altri interessi di controllo.

El 15/07/2025, CVI Investments, Inc. y su gestor de inversiones Heights Capital Management, Inc. presentaron conjuntamente un Schedule 13G reportando una posesión pasiva de 1,000,000 acciones ordinarias de BriaCell Therapeutics Corp. (CUSIP 107930208). La participación equivale al 5.7% de las 17.55 millones de acciones en circulación, según el prospecto de BriaCell de julio de 2025. Cada persona informante declara 0 poder de voto y disposición exclusivo y 1,000,000 compartidos. Ambas entidades niegan la propiedad beneficiaria más allá de su interés económico y certifican que las acciones no fueron adquiridas para influir en el control. Firmante: Sarah Travis (Heights Capital) el 22/07/2025. No se revelan arreglos grupales, subsidiarias ni otros intereses de control adicionales.

2025년 7월 15일, CVI Investments, Inc.와 투자 관리자 Heights Capital Management, Inc.는 공동으로 Schedule 13G를 제출하여 1,000,000주 BriaCell Therapeutics Corp. 보통주 (CUSIP 107930208)에 대한 수동적 소유권을 보고했습니다. 이 지분은 BriaCell의 2025년 7월 투자설명서에 명시된 17.55백만 주 중 5.7%에 해당합니다. 각 보고자는 단독 투표 및 처분 권한 0주공동 투표 및 처분 권한 1,000,000주를 주장합니다. 양 기관은 금전적 이익을 초과하는 실질적 소유권을 부인하며, 주식이 지배권 영향을 목적으로 취득되지 않았음을 인증합니다. 서명자: Sarah Travis (Heights Capital), 2025년 7월 22일. 그룹 협약, 자회사 또는 추가 지배권은 공개되지 않았습니다.

Le 15/07/2025, CVI Investments, Inc. et son gestionnaire d'investissement Heights Capital Management, Inc. ont conjointement déposé un Schedule 13G déclarant une participation passive de 1 000 000 actions ordinaires de BriaCell Therapeutics Corp. (CUSIP 107930208). Cette participation représente 5,7 % des 17,55 millions d'actions en circulation, comme indiqué dans le prospectus de BriaCell de juillet 2025. Chaque personne déclarante revendique 0 pouvoir de vote et de disposition exclusif et 1 000 000 partagé. Les deux entités déclinent toute propriété bénéficiaire au-delà de leur intérêt pécuniaire et certifient que les actions n'ont pas été acquises pour influencer le contrôle. Signataire : Sarah Travis (Heights Capital) le 22/07/2025. Aucun accord de groupe, filiale ou autre intérêt de contrôle n’est divulgué.

Am 15.07.2025 reichten CVI Investments, Inc. und ihr Investmentmanager Heights Capital Management, Inc. gemeinsam ein Schedule 13G ein, in dem ein passives Eigentum von 1.000.000 BriaCell Therapeutics Corp. Stammaktien (CUSIP 107930208) gemeldet wurde. Der Anteil entspricht 5,7 % der 17,55 Mio. ausstehenden Aktien, wie im Juli 2025 veröffentlichten Prospekt von BriaCell angegeben. Jede meldende Person beansprucht 0 alleinige und 1.000.000 gemeinsame Stimm- und Verfügungsrechte. Beide Einheiten lehnen eine wirtschaftliche Eigentümerschaft über ihr finanzielles Interesse hinaus ab und bestätigen, dass die Aktien nicht zum Zweck der Einflussnahme auf die Kontrolle erworben wurden. Unterzeichnerin: Sarah Travis (Heights Capital) am 22.07.2025. Es werden keine Gruppenvereinbarungen, Tochtergesellschaften oder weitere Kontrollinteressen offengelegt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


SCHEDULE 13G



CVI Investments, Inc.
Signature:/s/ Sarah Travis
Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc.
Date:07/22/2025
Heights Capital Management, Inc.
Signature:/s/ Sarah Travis
Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary
Date:07/22/2025

Comments accompanying signature: Heights Capital Management, Inc. serves as authorized agent of CVI Investments, Inc. pursuant to a Limited Power of Attorney, a copy of which is attached as Exhibit I hereto.
Exhibit Information

EXHIBIT INDEX EXHIBIT DESCRIPTION ________ ________ I Limited Power of Attorney II Joint Filing Agreement

FAQ

How many BriaCell (BCTXZ) shares do CVI Investments and Heights Capital own?

They report 1,000,000 common shares of BriaCell Therapeutics Corp.

What percentage of BriaCell’s outstanding shares does the 1 M-share position represent?

The filing states the stake equals 5.7 % of BriaCell’s outstanding common shares.

Is the CVI/Heights Capital position passive or activist?

The Schedule 13G certification confirms the shares were acquired passively, with no intent to influence control.

Do CVI Investments or Heights Capital hold sole voting power over the shares?

No. They report 0 sole and 1,000,000 shared votes and dispositive power.

When was the event triggering the Schedule 13G filing?

The relevant event date is 07/15/2025, as disclosed in the filing.
BTC Digital

NASDAQ:BTCT

BTCT Rankings

BTCT Latest News

BTCT Latest SEC Filings

BTCT Stock Data

23.60M
9.08M
11.85%
13.31%
5.52%
Computer Hardware
Finance Services
Link
China
SHENZHEN